Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Jeffrey W. Albers sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $30.05, for a total value of $300,500.00. The transaction was disclosed in a legal filing with the SEC, […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Jeffrey W. Albers sold 10,000 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $30.05, for a total transaction of $300,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible […]
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective lifted by Raymond James from $85.00 to $100.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has a strong-buy rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its target price hoisted by research analysts at Wells Fargo & Company from $86.00 to $115.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price indicates a potential upside […]
HC Wainwright reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report released on Monday, Benzinga reports. HC Wainwright currently has a $85.00 price target on the biotechnology company’s stock. A number of other equities research analysts have also issued reports on BPMC. Barclays upped their target price on […]